No results for ‘’
Thyrocare Technologies Ltd
₹540.55
(1.15%)
Fri, 26 Jun 2026, 02:39 am
Health Services
Medical/Nursing Services
24.5KThyrocare Technologies EV/EBITDA Ratio
| Particulars | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 89.69 | 34.71 | 33.34 | 29.67 | 42.26 | 23.27 | 35.32 | 44.39 | 39.48 |
| Price to book ratio | 0 | 0 | 0 | 0 | 0 | 0 | 9.40 | 7.29 | 6.44 | 7.14 | 11.17 | 7.77 | 4.26 | 5.95 | 6.59 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | 0 | 12.62 | 9.08 | 7.04 | 6.04 | 9.67 | 6.96 | 4.32 | 5.49 | 5.26 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 40.62 | 29.17 | 27.80 | 15.57 | 41.13 | 36.68 | 17.44 | 19.11 | 18.73 |
| Enterprise value | 0 | 0 | 0 | 0 | 0 | 0 | 3722Cr | 3125Cr | 2757Cr | 2555Cr | 4670Cr | 3981Cr | 2151Cr | 3008Cr | 3446Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 0 | 0 | 31.56 | 21.10 | 17.76 | 14.38 | 26.55 | 16.71 | 17.17 | 21.05 | 17.80 |
| Debt to equity ratio | 0.37 | 0.24 | 0.16 | 0.12 | 0 | 0 | 0 | 0 | 0.01 | 0.03 | 0.02 | 0.04 | 0.04 | 0.08 | 0.05 |
| Return on equity % | 0 | 41.11 | 43.28 | 25.20 | 18.57 | 16.18 | 11.08 | 21.95 | 19.39 | 22.05 | 28.50 | 36.93 | 12.16 | 13.34 | 17.05 |
Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio
The Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Thyrocare Technologies Ltd's valuation, profitability, and overall financial performance. Tracking the Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Thyrocare Technologies Ltd (NSE: THYROCARE, BSE: 539871) is currently trading at ₹540.55, with a market capitalization of ₹8501.82Cr. As a leading company in the Health services sector and Medical/Nursing services industry, monitoring the Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio Current Value
The current Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio stands at 17.80.
The Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 17.80
- 2023: 21.05
- 2022: 17.17
- 2021: 16.71
- 2020: 26.55
The decline in Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Thyrocare Technologies Ltd.
Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Thyrocare Technologies Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.